Skip to content
Hair Pipeline
← Back to the pipeline

AD-208

An undisclosed Addpharma candidate at phase 3 in androgenetic alopecia.

Phase 3OralUndisclosed

No public activity in over 18 months

Developed by
Addpharma
Current phase
Phase 3

Large confirmatory trials. The last step before filing.

Indications
Androgenetic alopecia
Also known as
AD-2081, AD208
Last public activity
July 2023
Record confidence
Low

Why it matters

Listed because it exists, not because anything is known about it. Two registered trials, one of them a pharmacokinetic study, and no disclosed composition or mechanism. It is in the register so that a reader who encounters the code has somewhere to check, and so that this row is already here when the sponsor does disclose.

Development history

  1. Phase 1Phase 3

    First Phase 3 trial on record: NCT04825561 — A Study to Evaluate the Efficacy and Safety of AD-208

    ClinicalTrials.gov ↗
  2. Phase 1

    First Phase 1 trial on record: NCT04214808 — To Evaluate the Pharmacokinetics and Safety of AD-208

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT04825561Phase 3COMPLETED

    A Study to Evaluate the Efficacy and Safety of AD-208

    Addpharma Inc. · n=139 · June 2021

  • NCT04214808Phase 1COMPLETED

    To Evaluate the Pharmacokinetics and Safety of AD-208

    Addpharma Inc. · n=24 · January 2020

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources